1.00 / AMA PRA Category 1 CreditTM 1.00 / CE for Nurse Practitioners
Jointly provided by Global Education Group and Physicians' Education Resource®, LLC (PER®)
This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.
Atherosclerosis, formerly considered a bland lipid storage disease, actually involves an ongoing inflammatory response. Recent advances in basic science have established a fundamental role for inflammation in mediating all stages of this disease from initiation through progression and, ultimately, the thrombotic complications of atherosclerosis. These new insights into inflammation in atherosclerosis not only increase our understanding of this disease, but also have practical clinical applications in risk stratification and targeting of therapy for this scourge of growing worldwide importance.
Physicians, nurse practitioners, and physician assistants involved in the care of patients with inflammation
At the conclusion of this activity, participants should be better able to:
Articulate the role of inflammation in the pathogenesis of atherosclerosis
Describe best practices for incorporating inflammatory biomarkers into cardiovascular risk assessment procedures to prevent secondary cardiovascular disease (CVD) risk
List the pleiotropic effects of statins, specifically their anti-inflammatory properties
Summarize recent data on emerging agents that target inflammation for secondary prevention of CVD in order to provide optimal outcomes for patients at risk
Disclosure of Conflicts of Interest Policy
Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
Christie M. Ballantyne, MD Professor of Medicine, Department of Medicine Chief, Section of Cardiology Chief, Section of Cardiovascular Research Baylor College of Medicine
Director, Center for Cardiovascular Disease Prevention DeBakey Heart and Vascular Center Houston Methodist Hospital Houston, TX
Dr. Ballantyne has the following relevant financial relationships with commercial interests to disclose: Grant/Research Support: Abbott Diagnostic, Amarin, Amgen, Esperion, Ionis, Novartis, Pfizer, Regeneron, Roche Diagnostic, Sanofi-Synthelabo, NIH, AHA, and ADA Consultant: Abbott Diagnostics, Amarin, Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Esperion, Ionis, Matinas BioPharma Inc, Merck, Novartis, Pfizer, Regeneron, Roche Diagnostic, and Sanofi-Synthelabo
Peter Libby, MD Brigham and Women’s Hospital Cardiovascular Medicine Harvard Medical School Boston, MA
Dr. Libby has the following relevant financial relationships with commercial interests to disclose: Grant/Research Support: Novartis Consultant: Novartis
Paul M. Ridker, MD Eugene Braunwald Professor of Medicine Harvard Medical School Director, Center for Cardiovascular Disease Prevention Brigham and Women’s Hospital Boston, MA
Dr. Ridker has the following relevant financial relationships with commercial interests to disclose: Grant/Research Support: AstraZeneca, Novartis, Pfizer, Kowa, and Amgen Consultant: Sanofi, Quintiles, AstraZeneca, and TEVA Patents Licensed: Siemen, AstraZeneca Research Funding Support: National Lung, Heart and Blood Institute, The National Cancer Institute, The American Heart Association, The Doris Duke Charitable Foundation, The Leducq Foundation, The Donald W Reynolds Foundation, and The James and Polly Annenberg La Vea Charitable Trusts
Robert S. Rosenson, MD Director, Cardiometabolics Unit Mount Sinai Hospital Professor of Medicine (Cardiology) Icahn School of Medicine at Mount Sinai New York, NY
Dr. Rosenson has the following relevant financial relationships with commercial interests to disclose: Grant/Research Support: Akcea, Amgen, AstraZeneca, Esperion, Medicines Company, and Regeneron Consultant: Amgen, CVS Caremark, C5, Regeneron, and Sanofi Honoraria: Kowa Other: UpToDate, Inc.
Accredited Provider Disclosure
Global Education Group Planners/Managers: Kristen Delisi, NP, Amanda Glazar, PhD, Laura Gilsdorf, and Andrea Funk have no relevant financial relationships with commercial interests to disclose.
Publishing Staff Disclosures
Physicians' Education Resource®, LLC (PER®) Planning Staff: David Heckard, Maryjo Dixon, RPh, Donna Fausak, and Nicole Grassano have no relevant financial relationships with commercial interests to disclose.
AMA PRA Category 1 Credit(s)TM
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Physicians' Education Resource®, LLC (PER®). Global is accredited by the ACCME to provide continuing medical education for physicians.
Global Education Group designates this enduring activity for a maximum of 1.00 AMA PRA Category 1 CreditTM . Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CE for Nurse Practitioners
Global Education Group is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 1561024
This activity is accredited for 1.00 contact hour which includes 0.00 hour(s) of pharmacology.
Activity ID 2239E
This activity was planned in accordance with AANP CE Standards and Policies.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and PER do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
To obtain credit, a score of 70% or better on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.